BRPI0514584A - método para preparar irbesartan e intermediários do mesmo - Google Patents

método para preparar irbesartan e intermediários do mesmo

Info

Publication number
BRPI0514584A
BRPI0514584A BRPI0514584-8A BRPI0514584A BRPI0514584A BR PI0514584 A BRPI0514584 A BR PI0514584A BR PI0514584 A BRPI0514584 A BR PI0514584A BR PI0514584 A BRPI0514584 A BR PI0514584A
Authority
BR
Brazil
Prior art keywords
intermediates
irbesartan
preparing
preparing irbesartan
intermediaries
Prior art date
Application number
BRPI0514584-8A
Other languages
English (en)
Inventor
Edgar I Miranda
Cornelis Vlaar
Jingyang Zhu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0514584A publication Critical patent/BRPI0514584A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

MéTODO PARA PREPARAR IRBESARTAN E INTERMEDIáRIOS DO MESMO. Refere-se a método para preparar irbesartan e intermediários dos mesmos. Irbesartan tem a estrutura de fórmula I.
BRPI0514584-8A 2004-08-23 2005-08-23 método para preparar irbesartan e intermediários do mesmo BRPI0514584A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60360604P 2004-08-23 2004-08-23
PCT/US2005/029879 WO2006023889A2 (en) 2004-08-23 2005-08-23 A method for preparing irbesartan and intermediates thereof

Publications (1)

Publication Number Publication Date
BRPI0514584A true BRPI0514584A (pt) 2008-06-17

Family

ID=35968277

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514584-8A BRPI0514584A (pt) 2004-08-23 2005-08-23 método para preparar irbesartan e intermediários do mesmo

Country Status (21)

Country Link
US (2) US7211676B2 (pt)
EP (1) EP1781627B1 (pt)
JP (1) JP5203703B2 (pt)
KR (1) KR101252309B1 (pt)
CN (1) CN101006064B (pt)
AR (1) AR050709A1 (pt)
AT (1) ATE488508T1 (pt)
AU (1) AU2005277162B2 (pt)
BR (1) BRPI0514584A (pt)
CA (2) CA2578409A1 (pt)
DE (1) DE602005024819D1 (pt)
ES (1) ES2357393T3 (pt)
HK (1) HK1098157A1 (pt)
IL (1) IL181464A (pt)
MX (1) MX2007002030A (pt)
NO (1) NO20071254L (pt)
PE (1) PE20060650A1 (pt)
RU (1) RU2388753C2 (pt)
TW (1) TWI346108B (pt)
WO (1) WO2006023889A2 (pt)
ZA (1) ZA200701363B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1918288A1 (en) 2006-11-02 2008-05-07 Cadila Pharmaceuticals Limited A novel and improved process for the preparation of Irbesartan, an angiotensin-II receptor antagonist for the treatment of hypertension
GB0700993D0 (en) * 2007-01-18 2007-02-28 Rainbow Engineering Services Novel compounds
WO2008107799A2 (en) * 2007-03-06 2008-09-12 Actavis Group Ptc Ehf Improved process for preparing irbesartan
SI22488A (sl) * 2007-04-24 2008-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalni 1-(cikloheksiloksikarboniloksi)etil 1-((2'-cianobifenil-4-il)metil) - 2-etoksi-1h-benz(d)imidazol -7-karboksilat in proces za njegovo pripravo
HUP0900788A2 (en) * 2009-12-16 2011-11-28 Sanofi Aventis Process for producing 4-bromomethyl-biphenyl derivatives
EP2719686B1 (en) * 2010-03-12 2015-12-02 Nippon Soda Co., Ltd. Process to halogenate a picoline derivative
CN102807564A (zh) * 2012-08-30 2012-12-05 珠海润都制药股份有限公司 厄贝沙坦的制备方法
CN102898420B (zh) * 2012-09-10 2014-10-29 珠海保税区丽珠合成制药有限公司 一种厄贝沙坦的合成路线及制备方法
CN103497178B (zh) * 2013-09-27 2015-04-08 中国药科大学 厄贝沙坦瑞格列奈共无定型物
CN104744303B (zh) * 2015-02-15 2017-06-23 北京欣奕华科技有限公司 2‑r‑4’‑溴甲基联苯及其制备方法
CN108164434A (zh) * 2017-12-27 2018-06-15 安徽太主科技发展有限公司 一种低成本4′-溴甲基-2-氰基联苯的制备方法
US11655220B2 (en) 2020-10-22 2023-05-23 Hetero Labs Limited Process for the preparation of angiotensin II receptor blockers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
TW201738B (pt) * 1990-03-20 1993-03-11 Sanofi Co
US5541209A (en) * 1994-08-22 1996-07-30 Bristol-Myers Squibb Company Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative
FR2725987B1 (fr) * 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
JP3003030B2 (ja) * 1997-05-26 2000-01-24 武田薬品工業株式会社 アミノベンゼン化合物の製造法
FR2766821A1 (fr) 1997-07-29 1999-02-05 Sanofi Sa Derives de 1,3-oxazolinyl-biphenyle, leur procede de preparation et leur utilisation comme intermediaires de synthese
US6162922A (en) * 1998-01-30 2000-12-19 Bristol-Myers Squibb Co. Method for preparing N-substituted heterocyclic derivatives using a phase-transfer catalyst
FR2780403B3 (fr) 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
CN100418962C (zh) * 2002-10-28 2008-09-17 南京长澳医药科技有限公司 一种厄贝沙坦合成工艺
WO2004065383A2 (en) * 2003-01-16 2004-08-05 Teva Pharmaceutical Industries Ltd. Novel synthesis of irbesartan

Also Published As

Publication number Publication date
KR20070045275A (ko) 2007-05-02
TWI346108B (en) 2011-08-01
ATE488508T1 (de) 2010-12-15
AU2005277162B2 (en) 2010-12-16
ES2357393T3 (es) 2011-04-26
RU2007109330A (ru) 2008-09-27
CN101006064A (zh) 2007-07-25
IL181464A (en) 2011-08-31
HK1098157A1 (en) 2007-07-13
US7365208B2 (en) 2008-04-29
IL181464A0 (en) 2007-07-04
KR101252309B1 (ko) 2013-04-08
MX2007002030A (es) 2007-03-28
EP1781627A2 (en) 2007-05-09
NO20071254L (no) 2007-03-22
CN101006064B (zh) 2011-01-26
US20070167634A1 (en) 2007-07-19
DE602005024819D1 (de) 2010-12-30
US7211676B2 (en) 2007-05-01
CA2754633A1 (en) 2006-03-02
WO2006023889A3 (en) 2006-09-08
AR050709A1 (es) 2006-11-15
WO2006023889A2 (en) 2006-03-02
JP5203703B2 (ja) 2013-06-05
US20060041147A1 (en) 2006-02-23
CA2578409A1 (en) 2006-03-02
JP2008510819A (ja) 2008-04-10
EP1781627B1 (en) 2010-11-17
ZA200701363B (en) 2008-06-25
EP1781627A4 (en) 2009-09-02
PE20060650A1 (es) 2006-07-09
RU2388753C2 (ru) 2010-05-10
AU2005277162A1 (en) 2006-03-02
TW200619205A (en) 2006-06-16

Similar Documents

Publication Publication Date Title
BRPI0514584A (pt) método para preparar irbesartan e intermediários do mesmo
CR20120011A (es) Inhibidores de bace
SV2010003718A (es) Inhibidores de bace
EA200702464A1 (ru) Способы получения фенольных 4-бифенилилазетидин-2-онов
AR050254A1 (es) Intermediarios y procesos para preparar dichos intermediarios utiles en la fabricacion de pirrolotriazinas
UY27748A1 (es) Derivados de quinolina e isoquinolina, un método para su obtención y su uso como inhibidores de la inflamación.
PA8676201A1 (es) Metodos para sintetizar 3-cianoquinolinas sustituidad y sus intermediarios
PA8791801A1 (es) Compuestos de pirazol
CR8358A (es) Pentalones transpuestos, un metodo para prepararlos y su uso como antiinflamatorios
PA8657801A1 (es) Aminalcoholes triciclicos, procedimientos para su preparacion
ATE554066T1 (de) Entzündungshemmende substituierte cyclobutendionverbindungen
UY29434A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como inhibidores de la inflamacinn
GT200800251A (es) Nitrilos espirociclicos como inhibidores de proteasa
ECSP088740A (es) Derivados de tetrahidronaftalina, procedimientos para prepararlos y su uso como antiinflamatorios
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
ECSP077306A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparación y su uso como antiinflamatorios
UY29481A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como antiinflamatorios.
EA200702428A1 (ru) Способы получения 4-бифенилилазетидин-2-онов
GT200600010A (es) Procedimientos para la preparacion de alcoholes aminoetoxibencilicos
UY29435A1 (es) Derivados de 5h-benzociclohepteno, procedimientos para su preparación y su uso como antiinflamatorios.
CL2011000932A1 (es) Proceso para la preparacion de 9-diclorometilen-1,2,3,3-tetrahidro-1,4-metano-naftalen-5-ilamina; compuesto intermedio y proceso para preparar 6,6-diclorfulveno.
DOP2006000089A (es) Derivados de tetrahidronaftalina, procedimientos para su preparacion y uso como antiinflamatorios.
DOP2006000064A (es) Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como inhibidores de la inflamacion
UY29309A1 (es) Aminoalcoholes tricíclicos, procedimientos para su preparación y su uso como inhibidores de inflamación
UY28907A1 (es) Derivados de cromanol, un procedimiento para su preparación y su uso como inhibidores de la inflamación.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2320 DE 23-06-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.